Comments to FDA: Scientific Data About Products Containing Cannabis or Cannabis Derived Compounds

Share page:

Comments | Jul 16, 2019

Docket Number:
DA-2019-N-1482

As many dietary supplement products are being marketed as containing cannabidiol (CBD), CHPA has an interest in this subject and we presented oral comments at FDA’s May 31, 2019, public hearing. These written comments supplement our oral remarks.

Related Posts

Press Releases and Statements

CHPA Welcomes Three Consumer Healthcare Industry Members

Press Releases and Statements

CHPA Statement Regarding ODSP Leadership

Press Releases and Statements

CHPA Applauds the Re-introduction of Bipartisan CBD Legislation